<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105771">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753362</url>
  </required_header>
  <id_info>
    <org_study_id>1965</org_study_id>
    <nct_id>NCT01753362</nct_id>
  </id_info>
  <brief_title>Liraglutide In Overweight Patients With Type 1 Diabetes</brief_title>
  <official_title>LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of liraglutide (a drug used to treat
      type 2 diabetes) on glucose (sugar) control over the 52 week study period when used in
      addition to insulin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study is to detect a difference in HbA1c after 26 weeks of treatment with Liraglutide or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference from baseline in mean weekly glucose concentrations</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous daily injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous daily injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as
        insulin pump) or multiple (four or more) injections of insulin per day. 2) Using a
        continuous glucose monitoring device (CGM) or regularly measuring their blood sugars four
        times daily. 3) HbA1c of less than 8.5%. 4) Well versed with carbohydrate counting. 5) Age
        18-75 years 6) BMIâ‰¥ 25kg/m2 7) Age at diagnosis of type 1 diabetes should be &lt;30 years. 8)
        evidence of auto-immunity to beta cells (GAD-65 and islet cell antibody screen)

        Exclusion Criteria:

        1)Type 1 diabetes for less than 6 months; 2)Coronary event or procedure (myocardial
        infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in
        the previous four weeks; 3)Hepatic disease (transaminase &gt; 3 times normal) or cirrhosis;
        4)Renal impairment (serum eGFR &lt;30ml/min/1.73m2); 5)HIV or Hepatitis B or C positive
        status; 6)Participation in any other concurrent clinical trial; 7)Any other
        life-threatening, non-cardiac disease; 8)Use of an investigational agent or therapeutic
        regimen within 30 days of study. 9) history of pancreatitis 10) pregnancy 11) inability to
        give informed consent 12) history of gastroparesis 13)history of medullary thyroid
        carcinoma or MEN 2 syndrome. 14) Smokers will be advised not to change their amount of
        smoking for the duration of the study; 15) Use of any agent other than insulin for
        treatment of diabetes (metformin, pramlintide or thiazolidinediones.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY UB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sandeep dhindsa, MBBS</last_name>
    <phone>716-626-7998</phone>
    <email>sdhindsa@kaleidahealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>SUNY at UB, 115 flint road,</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>sandeep dhindsa, MBBS</last_name>
      <phone>716-626-7998</phone>
      <email>sdhindsa@kaleidahealth.org</email>
    </contact>
    <investigator>
      <last_name>paresh dandona, mbbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>diabetes endocrinology center of WNY</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Williams</last_name>
      <phone>716-626-7998</phone>
      <email>swilliams3@kaleidahealth.org</email>
    </contact>
    <investigator>
      <last_name>Paresh Dandona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
